Literature DB >> 23801163

[Personalized urooncology based on molecular uropathology: part 1: what is diagnostic routine?].

C G Stöhr1, R Stöhr, A Rogler, K Amann, R Knüchel-Clarke, A Hartmann.   

Abstract

The approval of new therapeutic procedures for the three main malignancies of the urogenital tract in recent years has generated a need for personalization of urooncology. As a consequence the diagnostic procedures are no longer limited to histology and immunohistochemistry but also include the analysis of genetic alterations (mutations and chromosomal aberrations).

Entities:  

Mesh：

Year:  2013        PMID： 23801163     DOI： 10.1007/s00120-013-3228-z

Source DB:  PubMed          Journal:  Urologe A        ISSN： 0340-2592            Impact factor:   0.639


  22 in total

1.  Multi-target fluorescence in situ hybridization in bladder washings for prediction of recurrent bladder cancer.

Authors:  Tobias Zellweger; Gabriel Benz; Gieri Cathomas; Michael J Mihatsch; Tullio Sulser; Thomas C Gasser; Lukas Bubendorf
Journal:  Int J Cancer       Date:  2006-10-01       Impact factor: 7.396

Review 2.  Molecular pathways of urothelial development and bladder tumorigenesis.

Authors:  Mireia Castillo-Martin; Josep Domingo-Domenech; Orit Karni-Schmidt; Tulio Matos; Carlos Cordon-Cardo
Journal:  Urol Oncol       Date:  2010 Jul-Aug       Impact factor: 3.498

3.  Molecular confirmation of t(6;11)(p21;q12) renal cell carcinoma in archival paraffin-embedded material using a break-apart TFEB FISH assay expands its clinicopathologic spectrum.

Authors:  Pedram Argani; Raluca Yonescu; Laura Morsberger; Kerry Morris; George J Netto; Nathan Smith; Nilda Gonzalez; Peter B Illei; Marc Ladanyi; Constance A Griffin
Journal:  Am J Surg Pathol       Date:  2012-10       Impact factor: 6.394

Review 4.  Role of immunohistochemistry in diagnosing renal neoplasms: when is it really useful?

Authors:  Steven S Shen; Luan D Truong; Marina Scarpelli; Antonio Lopez-Beltran
Journal:  Arch Pathol Lab Med       Date:  2012-04       Impact factor: 5.534

5.  The predictive value of multi-targeted fluorescent in-situ hybridization in patients with history of bladder cancer.

Authors:  Ofer N Gofrit; Kevin C Zorn; Josephine Silvestre; Arieh L Shalhav; Gregory P Zagaja; Lambda P Msezane; Gary D Steinberg
Journal:  Urol Oncol       Date:  2008-02-20       Impact factor: 3.498

6.  Combinations of urinary biomarkers for surveillance of patients with incident nonmuscle invasive bladder cancer: the European FP7 UROMOL project.

Authors:  Tahlita C M Zuiverloon; Willemien Beukers; Kirstin A van der Keur; Annemieke J M Nieuweboer; Thomas Reinert; Lars Dyrskjot; Torben F Orntoft; Ellen C Zwarthoff
Journal:  J Urol       Date:  2012-11-28       Impact factor: 7.450

7.  Molecular grading of urothelial cell carcinoma with fibroblast growth factor receptor 3 and MIB-1 is superior to pathologic grade for the prediction of clinical outcome.

Authors:  Bas W G van Rhijn; André N Vis; Theo H van der Kwast; Wim J Kirkels; François Radvanyi; Engelbert C M Ooms; Dominique K Chopin; Egbert R Boevé; Adriaan C Jöbsis; Ellen C Zwarthoff
Journal:  J Clin Oncol       Date:  2003-05-15       Impact factor: 44.544

8.  CK20 and Ki-67 as significant prognostic factors in human bladder carcinoma.

Authors:  Yong-kang Ye; Xue-cheng Bi; Hui-chan He; Zhao-dong Han; Qi-shan Dai; Yu-xiang Liang; Guo-hua Zeng; Wei-jun Qin; Zhi-nan Chen; Wei-de Zhong
Journal:  Clin Exp Med       Date:  2010-01-13       Impact factor: 3.984

9.  A Decade of FGF Receptor Research in Bladder Cancer: Past, Present, and Future Challenges.

Authors:  Erica di Martino; Darren C Tomlinson; Margaret A Knowles
Journal:  Adv Urol       Date:  2012-07-31

10.  Oncogenic FGFR3 gene fusions in bladder cancer.

Authors:  Sarah V Williams; Carolyn D Hurst; Margaret A Knowles
Journal:  Hum Mol Genet       Date:  2012-11-21       Impact factor: 6.150
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.